Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Moritz Koch

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Oncotarget|December 9, 2014
Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancerChristoph Kahlert, Maria Fiala, Gabriel Musso, et al.
BMC Cancer|April 15, 2011
Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancerCarmen Timke, Hubertus Schmitz Winnenthal, Felix Klug, et al.
The Journal of Clinical Investigation|January 7, 2015
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosisChristoph Reissfelder, Slava Stamova, Christina Gossmann, et al.
BMC Cancer|July 14, 2012
A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcomaFalk Roeder, Daniela Schulz-Ertner, Anna V Nikoghosyan, et al.
BMC Cancer|August 22, 2012
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancerAndreas G Niethammer, Heinz Lubenau, Gerd Mikus, et al.
Annals of Surgical Oncology|August 11, 2012
Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapyChristoph Kahlert, Eva Gaitzsch, Gunnar Steinert, et al.
International Journal of Cancer|May 8, 2015
Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancerChristoph Kahlert, Tristan Lerbs, Mathieu Pecqueux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2011
Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitroChristoph Kahlert, Saleh Lahes, Praveen Radhakrishnan, et al.
EMBO Molecular Medicine|May 21, 2017
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenograftsClaudia R Ball, Felix Oppel, Karl Roland Ehrenberg, et al.
Surgery|February 15, 2011
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver SurgeryMoritz Koch, O James Garden, Robert Padbury, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Oncotarget|December 9, 2014
Prognostic impact of a compartment-specific angiogenic marker profile in patients with pancreatic cancerChristoph Kahlert, Maria Fiala, Gabriel Musso, et al.
BMC Cancer|April 15, 2011
Randomized controlled phase I/II study to investigate immune stimulatory effects by low dose radiotherapy in primarily operable pancreatic cancerCarmen Timke, Hubertus Schmitz Winnenthal, Felix Klug, et al.
The Journal of Clinical Investigation|January 7, 2015
Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosisChristoph Reissfelder, Slava Stamova, Christina Gossmann, et al.
BMC Cancer|July 14, 2012
A clinical phase I/II trial to investigate preoperative dose-escalated intensity-modulated radiation therapy (IMRT) and intraoperative radiation therapy (IORT) in patients with retroperitoneal soft tissue sarcomaFalk Roeder, Daniela Schulz-Ertner, Anna V Nikoghosyan, et al.
BMC Cancer|August 22, 2012
Double-blind, placebo-controlled first in human study to investigate an oral vaccine aimed to elicit an immune reaction against the VEGF-Receptor 2 in patients with stage IV and locally advanced pancreatic cancerAndreas G Niethammer, Heinz Lubenau, Gerd Mikus, et al.
Annals of Surgical Oncology|August 11, 2012
Expression analysis of aldehyde dehydrogenase 1A1 (ALDH1A1) in colon and rectal cancer in association with prognosis and response to chemotherapyChristoph Kahlert, Eva Gaitzsch, Gunnar Steinert, et al.
International Journal of Cancer|May 8, 2015
Overexpression of SIX1 is an independent prognostic marker in stage I-III colorectal cancerChristoph Kahlert, Tristan Lerbs, Mathieu Pecqueux, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 2, 2011
Overexpression of ZEB2 at the invasion front of colorectal cancer is an independent prognostic marker and regulates tumor invasion in vitroChristoph Kahlert, Saleh Lahes, Praveen Radhakrishnan, et al.
EMBO Molecular Medicine|May 21, 2017
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenograftsClaudia R Ball, Felix Oppel, Karl Roland Ehrenberg, et al.
Surgery|February 15, 2011
Bile leakage after hepatobiliary and pancreatic surgery: a definition and grading of severity by the International Study Group of Liver SurgeryMoritz Koch, O James Garden, Robert Padbury, et al.
Pageof 12